Share on StockTwits

Ironwood Pharmaceuticals (NASDAQ:IRWD) Insider Mark G. Currie sold 25,000 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $13.93, for a total value of $348,250.00. Following the transaction, the insider now directly owns 2,166 shares in the company, valued at approximately $30,172. The sale was disclosed in a document filed with the SEC, which is available at this link.

A number of research firms have recently commented on IRWD. Analysts at Leerink Swann raised their price target on shares of Ironwood Pharmaceuticals from $12.15 to $15.00 in a research note on Monday. They now have a “market perform” rating on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Ironwood Pharmaceuticals in a research note on Wednesday, April 30th. They now have a $22.00 price target on the stock. Finally, analysts at Cantor Fitzgerald reiterated a “hold” rating on shares of Ironwood Pharmaceuticals in a research note on Wednesday, April 30th. They now have a $11.00 price target on the stock. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and eight have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $13.59.

Shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) traded down 1.35% on Friday, hitting $13.91. The stock had a trading volume of 1,340,161 shares. Ironwood Pharmaceuticals has a 1-year low of $8.95 and a 1-year high of $15.47. The stock’s 50-day moving average is $11.80 and its 200-day moving average is $12.23. The company’s market cap is $1.920 billion.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Tuesday, April 29th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.06. The company had revenue of $14.60 million for the quarter, compared to the consensus estimate of $8.52 million. During the same quarter in the previous year, the company posted ($0.87) earnings per share. The company’s revenue for the quarter was up 342.4% on a year-over-year basis. On average, analysts predict that Ironwood Pharmaceuticals will post $-1.31 earnings per share for the current fiscal year.

Ironwood Pharmaceuticals, Inc is a pharmaceutical company, which discovers, develops and intends to commercialize differentiated medicines.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.